Background
Methods
Patients and controls
Group composition
Determination of HLA alleles
Statistical analysis
Results
ACL overall versus control group
ACL (n = 169) | Controls (n = 260) | ACL (n = 169) | Controls (n = 260) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allele
|
n
|
F
%
|
n
|
F %
|
P
-value
|
Pc-value
|
OR
|
95%CI
|
Allele
|
n
|
F%
|
n
|
F%
|
P
-value
|
Pc-value
|
OR
|
95%CI
|
HLA – A*
|
HLA-B*
| ||||||||||||||||
01
| 37 | 10.9 | 47 | 9.0 | ns | - |
07
| 20 | 5.9 | 38 | 7.3 | ns | - | ||||
02
| 95 | 28.1 | 127 | 24.4 | ns | - |
08
| 16 | 4.7 | 34 | 6.5 | ns | - | ||||
03
| 30 | 8.8 | 56 | 10.8 | ns | - |
13
| 1 | 0.3 | 9 | 1.7 | ns | - | ||||
11
| 23 | 6.8 | 26 | 5.0 | ns | - |
14
| 15 | 4.4 | 22 | 4.2 | ns | - | ||||
23
| 18 | 5.3 | 22 | 4.2 | ns | - |
15
| 26 | 7.7 | 48 | 9.2 | ns | - | ||||
24
| 37 | 10.9 | 62 | 11.9 | ns | - |
18
| 17 | 5.0 | 36 | 6.9 | ns | - | ||||
25
| 4 | 1.2 | 13 | 2.5 | ns | - |
27
| 7 | 2.1 | 8 | 1.5 | ns | - | ||||
26
| 11 | 3.2 | 18 | 3.5 | ns | - |
35
| 58 | 17.2 | 68 | 13.1 | ns | - | ||||
29
| 9 | 2.6 | 28 | 5.4 | ns | - |
37
| 1 | 0.3 | 5 | 1.0 | ns | - | ||||
30
| 11 | 3.2 | 25 | 4.8 | ns | - |
38
| 10 | 3.0 | 15 | 2.9 | ns | - | ||||
31
| 18 | 5.3 | 19 | 3.7 | ns | - |
39
| 13 | 3.9 | 18 | 3.5 | ns | - | ||||
32
| 8 | 2.3 | 16 | 3.1 | ns | - |
40
| 18 | 5.3 | 16 | 3.1 | ns | - | ||||
33
| 5 | 1.5 | 15 | 2.9 | ns | - |
41
| 2 | 0.6 | 6 | 1.2 | ns | - | ||||
34
| 3 | 0.9 | 5 | 1.0 | ns | - |
42
| 2 | 0.6 | 6 | 1.2 | ns | - | ||||
36
| 2 | 0.6 | 2 | 0.4 | ns | - |
44
| 43 | 12.7 | 46 | 8.9 | ns | - | ||||
39
| 1 | 0.3 | - | - | ns | - |
45
| 0 | - | 12 | 2.3 | 0.0046 | 0.1426 | - | - | ||
66
| 3 | 0.9 | 1 | 0.2 | ns | - |
46
| 0 | - | 4 | 0.8 | ns | - | ||||
68
| 19 | 5.62 | 35 | 6.7 | ns | - |
47
| 0 | - | 1 | 0.2 | ns | - | ||||
74
| 4 | 1.9 | 3 | 0.6 | ns | - |
48
| 3 | 0.9 | 2 | 0.4 | ns | - | ||||
HLA-DRB1*
|
49
| 8 | 2.4 | 8 | 1.5 | ns | - | ||||||||||
01
| 23 | 6.8 | 42 | 8.1 | ns | - |
50
| 8 | 2.4 | 14 | 2.7 | ns | - | ||||
03
| 32 | 9.5 | 61 | 11.7 | ns | - |
51
| 29 | 8.6 | 44 | 8.5 | ns | - | ||||
04
| 40 | 11.8 | 56 | 10.8 | ns | - |
52
| 10 | 3.0 | 11 | 2.1 | ns | - | ||||
07
| 39 | 11.5 | 67 | 12.9 | ns | - |
53
| 7 | 2.1 | 8 | 1.5 | ns | - | ||||
08
| 26 | 7.7 | 30 | 5.8 | ns | - |
54
| 1 | 0.3 | 3 | 0.6 | ns | - | ||||
09
| 4 | 1.2 | 4 | 0.8 | ns | - |
55
| 8 | 2.4 | 12 | 2.3 | ns | - | ||||
10
| 5 | 1.5 | 10 | 1.9 | ns | - |
56
| 2 | 0.6 | 1 | 0.2 | ns | - | ||||
11
| 45 | 13.3 | 81 | 15.6 | ns | - |
57
| 7 | 2.1 | 12 | 2.3 | ns | - | ||||
12
| 3 | 0.9 | 10 | 1.9 | ns | - |
58
| 6 | 1.8 | 10 | 1.9 | ns | - | ||||
13
| 51 | 15.1 | 54 | 10.4 | 0.0431 | 0.6465 | 1.53 | 1.01-2.31 |
73
| 0 | - | 1 | 0.2 | ns | - | ||
14
| 19 | 5.6 | 40 | 7.7 | ns | - |
81
| 0 | - | 2 | 3.9 | ns | - | ||||
15
| 34 | 10.1 | 44 | 8.8 | ns | - | |||||||||||
16
| 17 | 5.0 | 21 | 4.0 | ns | - |
Haplotypes | Frequency (%) | |||
---|---|---|---|---|
Controls (n=260) | ACL (n=169) |
P-value | OR (95%CI) | |
HLA-A*02-B*44-DRB1*07 | 0 (0.00%) | 4 (2.37%) | 0.0236 | - |
HLA-A*24-B*35-DRB1*01 | 0 (0.00%) | 4 (2.37%) | 0.0236 | - |
Group 1 versuscontrol group
ACL (group 1) (n = 136) | Controls (n = 260) | ACL (group 1) (n = 136) | Controls (n = 260) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allele
|
n
|
F
%
|
n
|
F %
|
P
-value
|
P
c-value
|
OR
|
95%CI
|
Allele
|
n
|
F %
|
n
|
F%
|
P
-value
|
P
c–value
|
OR
|
95%CI
|
HLA – A*
|
HLA-B*
| ||||||||||||||||
01
| 29 | 10.7 | 47 | 9.0 | ns | - |
07
| 15 | 5.5 | 38 | 7.3 | ns | - | ||||
02
| 73 | 26.8 | 127 | 24.4 | ns | - |
08
| 10 | 3.7 | 34 | 6.5 | ns | - | ||||
03
| 24 | 8.8 | 56 | 10.8 | ns | - |
13
| 1 | 0.4 | 9 | 1.7 | ns | - | ||||
11
| 18 | 6.6 | 26 | 5.0 | ns | - |
14
| 14 | 5.2 | 22 | 4.2 | ns | - | ||||
23
| 14 | 5.2 | 22 | 4.2 | ns | - |
15
| 23 | 8.5 | 48 | 9.2 | ns | - | ||||
24
| 28 | 10.3 | 62 | 11.9 | ns | - |
18
| 13 | 4.8 | 36 | 6.9 | ns | - | ||||
25
| 4 | 1.5 | 13 | 2.5 | ns | - |
27
| 3 | 1.1 | 8 | 1.5 | ns | - | ||||
26
| 8 | 2.9 | 18 | 3.5 | ns | - |
35
| 53 | 19.5 | 68 | 13.1 | 0.0218 | 0.6758 | 1.67 | 1.08-2.29 | ||
29
| 9 | 3.3 | 28 | 5.4 | ns | - |
37
| 1 | 0.4 | 5 | 1.0 | ns | - | ||||
30
| 9 | 3.3 | 25 | 4.8 | ns | - |
38
| 7 | 2.6 | 15 | 2.9 | ns | - | ||||
31
| 15 | 5.5 | 19 | 3.7 | ns | - |
39
| 10 | 3.7 | 18 | 3.5 | ns | - | ||||
32
| 7 | 2.6 | 16 | 3.1 | ns | - |
40
| 14 | 5.2 | 16 | 3.1 | ns | - | ||||
33
| 5 | 1.8 | 15 | 2.9 | ns | - |
41
| 2 | 0.7 | 6 | 1.2 | ns | - | ||||
34
| 3 | 1.1 | 5 | 1.0 | ns | - |
42
| 2 | 0.7 | 6 | 1.2 | ns | - | ||||
36
| 1 | 0.4 | 2 | 0.4 | ns | - |
44
| 38 | 14.0 | 46 | 8.9 | 0.0290 | 0.8990 | 1.67 | 1.05-2.64 | ||
39
| 1 | 0.4 | - | - | ns | - |
45
| 0 | - | 12 | 2.3 | 0.0107 | 0.3317 | - | - | ||
66
| 2 | 0.7 | 1 | 0.2 | ns | - |
46
| 0 | - | 4 | 0.8 | ns | - | ||||
68
| 19 | 7.0 | 35 | 6.7 | ns | - |
47
| 0 | - | 1 | 0.2 | ns | - | ||||
74
| 3 | 1.1 | 3 | 0.6 | ns | - |
48
| 3 | 1.1 | 2 | 0.4 | ns | - | ||||
HLA-DRB1*
|
49
| 4 | 1.5 | 8 | 1.5 | ns | - | ||||||||||
01
| 18 | 6.6 | 42 | 8.1 | ns | - |
50
| 6 | 2.2 | 14 | 2.7 | ns | - | ||||
03
| 22 | 8.1 | 61 | 11.7 | ns | - |
51
| 24 | 8.8 | 44 | 8.5 | ns | - | ||||
04
| 33 | 12.1 | 56 | 10.8 | ns | - |
52
| 6 | 2.2 | 11 | 2.1 | ns | - | ||||
07
| 33 | 12.1 | 67 | 12.9 | ns | - |
53
| 7 | 2.6 | 8 | 1.5 | ns | - | ||||
08
| 20 | 7.4 | 30 | 5.8 | ns | - |
54
| 0 | - | 3 | 0.6 | ns | - | ||||
09
| 4 | 1.5 | 4 | 0.8 | ns | - |
55
| 5 | 1.8 | 12 | 2.3 | ns | - | ||||
10
| 5 | 1.8 | 10 | 1.9 | ns | - |
56
| 1 | 0.3 | 1 | 0.2 | ns | - | ||||
11
| 33 | 12.1 | 81 | 15.6 | ns | - |
57
| 5 | 1.8 | 12 | 2.3 | ns | - | ||||
12
| 3 | 1.1 | 10 | 1.9 | ns | - |
58
| 5 | 1.8 | 10 | 1.9 | ns | - | ||||
13
| 44 | 16.2 | 54 | 10.4 | 0.0228 | 0.3420 | 1.66 | 1.08-2.55 |
73
| 0 | - | 1 | 0.2 | ns | - | ||
14
| 14 | 5.2 | 40 | 7.7 | ns | - |
81
| 0 | - | 2 | 3.9 | ns | - | ||||
15
| 28 | 10.3 | 44 | 8.8 | ns | - | |||||||||||
16
| 15 | 5.5 | 21 | 4.0 | ns | - |
Subgroup 1A versuscontrol group
ACL (group 1A) (n = 118) | Controls (n = 260) | ACL (group 1A) (n = 118) | Controls | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allele
|
n
|
F
%
|
n
|
F %
|
P
-value
|
P
c-value
|
OR
|
95%CI
|
Allele
|
n
|
F %
|
n
|
F %
|
P
-value
|
P
c-value
|
OR
|
95%CI
|
HLA – A*
|
HLA-B*
| ||||||||||||||||
01
| 26 | 11.0 | 47 | 9.0 | ns | - |
07
| 14 | 5.9 | 38 | 7.3 | ns | - | ||||
02
| 64 | 27.1 | 127 | 24.4 | ns | - |
08
| 10 | 4.2 | 34 | 6.5 | ns | - | ||||
03
| 21 | 8.9 | 56 | 10.8 | ns | - |
14
| 10 | 4.2 | 22 | 4.2 | ns | - | ||||
11
| 16 | 6.8 | 26 | 5.0 | ns | - |
15
| 22 | 9.3 | 48 | 9.2 | ns | - | ||||
24
| 24 | 10.2 | 62 | 11.9 | ns | - |
18
| 10 | 4.2 | 36 | 6.9 | ns | - | ||||
HLA-DRB1*
|
27
| 3 | 1.3 | 8 | 1.5 | ns | - | ||||||||||
01
| 16 | 6.8 | 42 | 8.1 | ns |
35
| 44 | 18.6 | 68 | 13.1 | ns | - | |||||
03
| 20 | 8.4 | 61 | 11.7 | ns | - |
39
| 8 | 3.4 | 18 | 3.5 | ns | - | ||||
04
| 27 | 11.4 | 56 | 10.8 | ns | - |
40
| 12 | 5.1 | 16 | 3.1 | ns | - | ||||
07
| 29 | 12.3 | 67 | 12.9 | ns | - |
44
| 35 | 14.8 | 46 | 8.9 | 0.0160 | 0.4969 | 1.79 | 1.12-2.87 | ||
08
| 17 | 7.2 | 30 | 5.8 | ns | - |
45
| 0 | - | 12 | 2.3 | 0.0231 | 0.0225 | - | - | ||
11
| 31 | 13.1 | 81 | 15.6 | ns | - |
49
| 3 | 1.3 | 8 | 1.5 | ns | - | ||||
13
| 38 | 16.1 | 54 | 10.4 | 0.0152 | 0.2280 | 1.65 | 1.06-2.59 |
51
| 20 | 8.5 | 44 | 8.5 | ns | - | ||
14
| 11 | 4.7 | 40 | 7.7 | ns |
52
| 6 | 2.5 | 11 | 2.1 | ns | - | |||||
15
| 24 | 10.2 | 44 | 8.8 | ns | - |
Preliminary results from the other groups and subgroups versus the control group
Allele | ACL | Controls (n = 260) |
P-value |
Pc-value | OR | 95%CI | ||
---|---|---|---|---|---|---|---|---|
n |
F% | n |
F %
| |||||
ACL overall (n = 169)
| ||||||||
HLA-B*45 | 0 | - | 12 | 2.3 | 0.0046 | 0.1426 | - | - |
HLA-DRB1*13 | 51 | 15.1 | 54 | 10.4 | 0.0431 | 0.6465 | 1.53 | 1.01-2.31 |
ACL (group 1; n = 136)
| ||||||||
HLA-DRB1*13 | 44 | 16.2 | 54 | 10.4 | 0.0228 | 0.3420 | 1.66 | 1.08-2.55 |
HLA-B*35 | 53 | 19.5 | 68 | 13.1 | 0.0218 | 0.6758 | 1.67 | 1.08-2.29 |
HLA-B*44 | 38 | 14.0 | 46 | 8.9 | 0.0290 | 0.8990 | 1.67 | 1.05-2.64 |
HLA-B*45 | 0 | - | 12 | 2.3 | 0.0107 | 0.3317 | - | - |
ACL (group 1A; n = 118)
| ||||||||
HLA-B*44 | 35 | 14.8 | 46 | 8.9 | 0.0160 | 0.4969 | 1.79 | 1.12-2.87 |
HLA-B*45 | 0 | - | 12 | 2.3 | 0.0231 | 0.0225 | - | - |
HLA-DRB1*13 | 38 | 16.1 | 54 | 10.4 | 0.0152 | 0.2280 | 1.65 | 1.06-2.59 |
ACL (group 2; n = 15)
| ||||||||
HLA-B*27 | 3 | 10.0 | 8 | 1.5 | 0.0180 | 0.5580 | 7.11 | 1.78-28.33 |
ACL (group 3B; n = 7)
| ||||||||
HLA-B*52 | 3 | 21.4 | 11 | 2.1 | 0.0044 | 0.1360 | 12.61 | 3.08-51.66 |
ACL (group 4; n = 22)
| ||||||||
HLA-B*49 | 4 | 9.1 | 8 | 1.5 | 0.0101 | 0.3131 | 6.4 | 1.8-22.17 |